| Literature DB >> 33209042 |
Qiuyang Deng1, Jinyong Zhang2, Min Zhang1, Zhou Liu3, Yuxin Zhong1, Shiyi Liu1, Ruiqin Cui1, Yun Shi2, Hao Zeng2, Xiyao Yang3, Chuchu Lin4, Yutian Luo5, Huaisheng Chen5, Weiyuan Wu6, Jinsong Wu6, Tianle Zhang7, Yuemei Lu6, Xueyan Liu5, Quanming Zou2, Wei Huang1.
Abstract
OBJECTIVE: We aimed to establish a tool for rapid identification of KL49 Acinetobacter baumannii.Entities:
Keywords: Acinetobacter baumannii; K locus; Kaptive; hypervirulent; mortality
Year: 2020 PMID: 33209042 PMCID: PMC7669520 DOI: 10.2147/IDR.S278891
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Distribution of KL49 Capsular Polysaccharide (CPS) Synthesis Genes in Other KL Types
| Gene Name | Proportion | Gene Name | Proportion |
|---|---|---|---|
| 92/92 | 1/92 | ||
| 92/92 | 92/92 | ||
| 92/92 | 13/92 | ||
| 92/92 | 13/92 | ||
| 14/92 | 13/92 | ||
| 14/92 | 7/92 | ||
| 14/92 | 3/92 | ||
| 8/92 | 7/92 | ||
| 8/92 | 35/92 | ||
| 14/92 | 92/92 | ||
| 2/92 | 92/92 | ||
| 2/92 | 92/92 | ||
| 2/92 | 72/92 | ||
| 89/92 | 92/92 |
KL Types of 61 Clinical Carbapenem Resistant Acinetobacter baumannii Strains in This Study
| Assembly | Strain | Best Match Locus | Match Confidence |
|---|---|---|---|
| GCA_007999645.1 | 1044 | KL3 | Very high |
| GCA_007999765.1 | 208210 | KL77 | Perfect |
| GCA_007999725.1 | 208211 | KL77 | Perfect |
| GCA_007999745.1 | 208212 | KL77 | Perfect |
| GCA_007999705.1 | 208213 | KL77 | Perfect |
| GCA_007999665.1 | 208214 | KL77 | Perfect |
| GCA_007999955.1 | 20821 | KL77 | Perfect |
| GCA_007999855.1 | 20822 | KL77 | Perfect |
| GCA_007999905.1 | 20823 | KL77 | Perfect |
| GCA_007999885.1 | 20824 | KL77 | Perfect |
| GCA_007999845.1 | 20825 | KL77 | Perfect |
| GCA_007999875.1 | 20826 | KL77 | Perfect |
| GCA_007999815.1 | 20827 | KL77 | Perfect |
| GCA_007999805.1 | 20828 | KL77 | Perfect |
| GCA_007999755.1 | 20829 | KL77 | Perfect |
| GCA_007999365.1 | 208510 | KL3 | High |
| GCA_007999525.1 | 20851 | KL3 | Very high |
| GCA_007999515.1 | 20852 | KL3 | Very high |
| GCA_007999505.1 | 20853 | KL3 | Very high |
| GCA_007999485.1 | 20854 | KL3 | Very high |
| GCA_007999465.1 | 20855 | KL3 | Very high |
| GCA_007999405.1 | 20856 | KL3 | Very high |
| GCA_007999395.1 | 20857 | KL3 | Very high |
| GCA_007999425.1 | 20858 | KL3 | Very high |
| GCA_007999375.1 | 20859 | KL3 | Very high |
| GCA_008000175.1 | 2087 | KL3 | High |
| GCA_007999985.1 | 20881 | KL2 | Very high |
| GCA_007999965.1 | 20882 | KL2 | Good |
| GCA_007999945.1 | 20883 | KL2 | Very high |
| GCA_007999625.1 | 2092 | KL49 | Very high |
| GCA_007999585.1 | 2093 | KL77 | Perfect |
| GCA_007999605.1 | 20941 | KL3 | Very high |
| GCA_007999635.1 | 20942 | KL3 | Very high |
| GCA_007999555.1 | 20943 | KL3 | Very high |
| GCA_008000185.1 | 2096 | KL14 | Low |
| GCA_008000165.1 | 5121 | KL49 | Very high |
| GCA_008000125.1 | 5122 | KL49 | Very high |
| GCA_008000095.1 | 5123 | KL49 | Very high |
| GCA_008000085.1 | 5124 | KL49 | Very high |
| GCA_008000065.1 | 5125 | KL49 | Good |
| GCA_008000075.1 | 5126 | KL49 | Very high |
| GCA_008000045.1 | 5127 | KL49 | Very high |
| GCA_008000025.1 | 5128 | KL49 | Very high |
| GCA_007999155.1 | 71510 | KL3 | Very high |
| GCA_007999145.1 | 71511 | KL3 | Very high |
| GCA_008000715.1 | 71512 | KL3 | Very high |
| GCA_007999045.1 | 71513 | KL3 | High |
| GCA_008000725.1 | 71514 | KL3 | High |
| GCA_007999055.1 | 71515 | KL3 | High |
| GCA_007999075.1 | 71516 | KL3 | High |
| GCA_008000225.1 | 71517 | KL3 | Very high |
| GCA_008000235.1 | 71518 | KL3 | High |
| GCA_007999345.1 | 7151 | KL3 | Very high |
| GCA_007999305.1 | 7152 | KL3 | Very high |
| GCA_007999275.1 | 7153 | KL3 | Very high |
| GCA_007999245.1 | 7154 | KL3 | Very high |
| GCA_007999295.1 | 7155 | KL3 | Very high |
| GCA_007999255.1 | 7156 | KL3 | Very high |
| GCA_007999225.1 | 7157 | KL3 | Very high |
| GCA_007999175.1 | 7158 | KL3 | Very high |
| GCA_007999165.1 | 7159 | KL3 | Very high |
Figure 1Virulence potential of Acinetobacter baumannii strains in a mouse infection model. (A–D) The effect of 2.5×108, 1×108, 5×107, 1×107 colony-forming units of each A. baumannii isolate (n=10; *P<0.05, **P<0.001, log-rank test) on survival was assessed in mouse. Strains 5122 and 2092 are two KL49 A. baumannii strains; 7152, 71517 and 20859 are KL3 A. baumannii strains. LAC-4 is a KL49 hypervirulent A. baumannii strain reported in a previous study. LAC-4:Δgtr100 is a gtr100 knockout strain. LAC-4:Δgtr100Ωgtr100 is complemented strain. ATCC17978 is a KL3 A. baumannii strain.
Figure 2Worldwide spread of KL49 Acinetobacter baumannii strains. (A) A phylogenetic tree of the 78 KL49 strains retrieved from NCBI and nine KL49 strains in this study. LAC-4 was used as reference. The colors of the isolate tips represent the country of isolation. STs are shown in the outer ring. (B) An unrooted version of the tree shown in (A).
Univariable Logistic Regression Analysis of the Factors Associated with Mortality
| Variables | Odds Ratio (95%CI) | |
|---|---|---|
| Demographics | ||
| Age (years) | ||
| 30–50 | 0.58 (0.20–1.66) | 0.306 |
| > 50 | 2.48 (0 0.89–6.94) | 0.083 |
| Gender (male) | 0.77 (0.36–1.61) | 0.481 |
| Infection Site | ||
| Bacteremia | 1.22 (0.34–4.38) | 0.755 |
| Pulmonary infection | 2.37 (0.91–6.16) | 0.077 |
| Urinary infection | 1.23 (0.50–2.99) | 0.652 |
| Abdominal infection | 1.28 (0.29–5.59) | 0.739 |
| Comorbidities | ||
| Cerebral vascular disease | 0.81 (0.42–1.56) | 0.523 |
| Hypertension | 1.61 (0.80–3.24) | 0.179 |
| Diabetes | 1.63 (0.83–3.21) | 0.159 |
| Coma | 3.43 (1.62–7.23) | 0.001 |
| Solid malignancy | 5.60 (1.84–17.10) | 0.002 |
| Invasive Procedures | ||
| Mechanical ventilation | 2.82 (1.25–6.37) | 0.012 |
| Central venous catheter | 1.77 (0.87–3.58) | 0.115 |
| Foley catheter | 2.14 (0 0.82–5.59) | 0.122 |
| Nasogastric tube | 1.39 (0.64–3.06) | 0.404 |
| Clinical Characteristics | ||
| Leukopenia (<4×109/L) | 3.78 (0.87–16.48) | 0.076 |
| Anemia (<10 g/dL) | 1.36 (0.66–2.82) | 0.407 |
| Platelet count (<50×109/L) (<50×109/L) (<50×109/L) | 3.61 (1.21–10.76) | 0.021 |
| Aspartate aminotransferase (>60 IU/L) | 1.44 (0.39–5.34) | 0.584 |
| Total bilirubin (>35 μmol/L) | 1.24 (0.49–3.18) | 0.648 |
| Urea nitrogen (>7.5mmol/L) | 3.19 (1.59–6.38) | 0.001 |
| C-reactive Protein (CRP) | ||
| 10–50 mg/L | 0.38 (0.18–0.78) | 0.008 |
| >50 mg/L | 4.41 (2.13–9.16) | < 0.001 |
| Procalcitionin (PCT) | ||
| 0.5–2 ug/L | 0.53 (0.26–1.08) | 0.08 |
| >2 ug/L | 3.02 (1.53–5.95) | 0.001 |
| Duration of ICU (days) | ||
| <7 | 1.56 (0.47–5.17) | 0.465 |
| 7–30 | 1.18. (0.60–2.31) | 0.627 |
| >30 | 1.02 (0.48–2.19) | 0.953 |
| Antibiotic Treatment | ||
| Cefoperazone/sulbactam | 0.93 (0.42–2.04) | 0.86 |
| Piperacillin/tazobactam | 1.34 (0.67–2.68) | 0.41 |
| Carbapenems | 1.12 (0.18–2.21) | 0.057 |
| Quinolone | 1.08 (0.54–2.15) | 0.826 |
| Third generation cephalosporins | 0.71 (0.34–1.45) | 0.342 |
| Aminoglycoside | 1.82 (0.81–4.09) | 0.149 |
| Minocycline | 1.14 (0.47–2.77) | 0.767 |
| Tigecycline | 3.12 (1.46–6.69) | 0.053 |
| Colistin | 1.06 (0.09–11.93) | 0.964 |
| Tigecycline + carbapenems | 2.97 (0.64–13.76) | 0.165 |
| Colistin + carbapenems | 2.13 (0.13–34.79) | 0.594 |
| Carbapenems + aminoglycoside | 0.41 (0.05–3.61) | 0.423 |
| Proportion of XDR strains | 0.79 (0.38–1.64) | 0.526 |
| Continuous renal replacement therapy | 2.74 (0.79–9.39) | 0.111 |
| Sepsis | 5.13 (2.01–13.07) | 0.001 |
| Shock | 9.52 (4.48–20.20) | <0.001 |
| Polymicrobial infection | 1.18 (0.61–2.30) | 0.622 |
| | 5.47 (2.42–12.33) | <0.001 |
Multivariable Logistic Regression Analysis of the Factors Associated with Mortality
| Variables | Odds Ratio (95%CI) | |
|---|---|---|
| Coma | 2.69 (0.87–8.33) | 0.085 |
| Solid malignancy | 13.66 (3.03–61.47) | 0.001 |
| Mechanical ventilation | 3.69 (1.01–13.61) | 0.049 |
| Urea nitrogen (>7.5mmol/L) | 4.03 (1.31–12.39) | 0.015 |
| C-reactive protein (CRP) >50 mg/L | 0.89 (0.26–3.11) | 0.858 |
| Procalcitionin (PCT) >2 ug/L | 2.46 (0.83–7.26) | 0.104 |
| Sepsis | 6.19 (1.61–23.84) | 0.008 |
| 10.76 (3.08–37.55) | <0.001 |